View Filing Data

Print Document View Excel Document

Document and Entity Information Document - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 14, 2016	Jun. 30, 2015
Document Information [Line Items]
Entity Registrant Name	CALADRIUS BIOSCIENCES, INC.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		59,030,599
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 94.6

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 20,318,411	$ 19,174,061
Marketable securities	0	7,080,053
Accounts receivable trade, net of allowance for doubtful accounts of $0 and $385,362 respectively	2,566,101	3,111,274
Deferred costs	2,911,743	2,566,989
Prepaids and other current assets	3,476,177	4,349,167
Total current assets	29,272,432	36,281,544
Property, plant and equipment, net	17,064,900	15,960,731
Goodwill	7,013,315	25,209,336
Intangible assets, net	2,877,880	47,560,406
Other assets	976,768	1,263,375
Total assets	57,205,295	126,275,392
Current Liabilities
Accounts payable	4,107,388	5,661,173
Accrued liabilities	6,198,488	4,322,901
Long-term debt, current	4,171,456	1,109,612
Notes payable	1,192,666	816,776
Unearned revenues	5,345,225	4,334,120
Total current liabilities	21,015,223	16,244,582
Deferred income taxes	932,662	18,176,190
Notes payable	583,041	825,897
Long term debt	10,828,544	13,890,388
Acquisition-related contingent consideration	0	18,260,000
Other long-term liabilities	562,001	804,546
Total liabilities	33,921,471	68,201,603
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2015 and December 31, 2014	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 56,733,012 and 36,783,857 shares, at December 31, 2015 and December 31, 2014, respectively	56,733	36,784
Additional paid-in capital	396,496,341	350,428,903
Treasury stock, at cost; 110,799 shares at December 31, 2015, and 109,989 shares at December 31, 2014	(707,637)	(705,742)
Accumulated deficit	(372,132,490)	(291,246,538)
Accumulated other comprehensive income	486	1,329
Total Caladrius Biosciences, Inc. stockholders' equity	23,713,533	58,514,836
Noncontrolling interests	(429,709)	(441,047)
Total equity	23,283,824	58,073,789
Liabilities and Equity, Total	$ 57,205,295	$ 126,275,392

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Allowance for doubtful accounts	$ 0	$ 385,362
Preferred Stock [Member]
Preferred stock, shares authorized (shares)	20,000,000	20,000,000
Series B Convertible Redeemable Preferred Stock [Member]
Preferred stock, liquidation preference (shares)	1	1
Preferred stock, par value (USD per share)	$ 0.01	$ 0.01
Preferred stock, shares designated (shares)	825,000	825,000
Preferred stock, shares issued (shares)	10,000	10,000
Preferred stock, shares outstanding (shares)	10,000	10,000
Common Stock [Member]
Common stock, par value (USD per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	500,000,000	500,000,000
Common stock, shares, issued (shares)	56,733,012	36,783,857
Common stock, shares, outstanding (shares)	56,733,012	36,783,857
Treasury Stock [Member]
Treasury Stock, Shares	110,799	109,989

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues	$ 22,487,566	$ 17,938,790	$ 14,668,455
Cost of revenues	20,158,828	15,678,475	12,947,217
Research and development	23,899,026	29,194,262	16,917,396
Impairment of Intangible Assets, Finite-lived	62,273,336	0	0
Selling, general, and administrative	30,005,542	30,806,807	21,612,793
Operating Expenses	136,336,732	75,679,544	51,477,406
Operating loss	(113,849,166)	(57,740,754)	(36,808,951)
Other income (expense):
Other (expense) income, net	17,723,579	2,926,003	(1,614,858)
Interest expense	(2,128,442)	(755,697)	(281,421)
Nonoperating Income (Expense), Total	15,595,137	2,170,306	(1,896,279)
Loss from operations before provision for income taxes and noncontrolling interests	(98,254,029)	(55,570,448)	(38,705,230)
Income Tax Expense (Benefit)	(17,243,528)	(104,202)	780,104
Net loss	(81,010,501)	(55,466,246)	(39,485,334)
Less - loss from continuing operations attributable to noncontrolling interests	(124,549)	(593,313)	(504,090)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (80,885,952)	$ (54,872,933)	$ (38,981,244)
Basic and diluted (loss) per share attributable to:
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (1.67)	$ (1.68)	$ (1.90)
Weighted average common shares outstanding	48,508,106	32,756,102	20,495,771

Consolidated Statements of Comprehensive income - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net loss	$ (81,010,501)	$ (55,466,246)	$ (39,485,334)
Other comprehensive income (loss):
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	(843)	1,329	0
Total other comprehensive income (loss)	(843)	1,329	0
Comprehensive loss	(81,011,344)	(55,464,917)	(39,485,334)
Comprehensive loss attributable to noncontrolling interests	(124,549)	(593,313)	(504,090)
Comprehensive net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (80,886,795)	$ (54,871,604)	$ (38,981,244)

Consolidated Statements of Equity - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total NeoStem, Inc. Shareholders' Equity [Member]	Non-Controlling Interest in Subsidiary [Member]
Beginning Balance (in shares) at Dec. 31, 2012		10,000	16,375,365
Beginning Balance at Dec. 31, 2012	$ 32,820,159	$ 100	$ 16,375	$ 231,218,615	$ 0	$ (197,392,361)	$ (665,600)	$ 33,177,129	$ (356,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(39,485,334)					(38,981,244)		(38,981,244)	(504,090)
Share-based compensation (in shares)			513,912
Share-based compensation	(6,838,559)		$ (514)	(6,878,187)			(40,142)	(6,838,559)
Proceeds from issuance of common stock (in shares)			9,712,724
Proceeds from issuance of common stock	58,736,166		$ 9,713	58,726,453				58,736,166
Proceeds from option exercises, shares			31,369
Proceeds from exercise of options	150,658		$ 31	150,627				150,658
Proceeds from warrant exercises (in shares)			563,167
Proceeds from warrant exercises	3,028,241		$ 564	3,027,677				3,028,241
Warrant inducements			0
other comprehensive income, foreign currency translation elimination on sale of segment					0
Stock Issued During Period, Value, Warrant Inducements	62,014		$ 0	62,014				62,014
Change in Ownership in Subsidiary	0			(345,020)				(345,020)	345,020
Ending Balance (in shares) at Dec. 31, 2013		10,000	27,196,537
Ending Balance at Dec. 31, 2013	62,026,435	$ 100	$ 27,197	299,594,525	0	(236,373,605)	(705,742)	62,542,475	(516,040)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(55,466,246)					(54,872,933)		(54,872,933)	(593,313)
Marketable Securities, Unrealized Gain (Loss)	1,329				1,329			1,329
Share-based compensation (in shares)			916,359
Share-based compensation	(11,209,542)		$ (916)	(11,208,626)			0	(11,209,542)
Proceeds from issuance of common stock (in shares)			2,959,214
Proceeds from issuance of common stock	16,710,645		$ 2,959	16,707,686				16,710,645
Proceeds from option exercises, shares			48,987
Proceeds from exercise of options	271,008		$ 49	270,959				271,008
Proceeds from warrant exercises (in shares)			333,250
Proceeds from warrant exercises	1,720,725		$ 333	1,720,392				1,720,725
Stock Issued During Period, Shares, Acquisitions			5,329,510
Stock Issued During Period, Value, Acquisitions	21,600,351		$ 5,330	21,595,021				21,600,351
Change in Ownership in Subsidiary	0			(668,306)				(668,306)	668,306
Ending Balance (in shares) at Dec. 31, 2014		10,000	36,783,857
Ending Balance at Dec. 31, 2014	58,073,789	$ 100	$ 36,784	350,428,903	1,329	(291,246,538)	(705,742)	58,514,836	(441,047)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(81,010,501)					(80,885,952)		(80,885,952)	(124,549)
Marketable Securities, Unrealized Gain (Loss)	(843)				(843)			(843)
Share-based compensation (in shares)			928,000
Share-based compensation	(9,750,110)		$ (928)	(9,751,077)			(1,895)	(9,750,110)
Proceeds from issuance of common stock (in shares)			19,021,155
Proceeds from issuance of common stock	36,471,269		$ 19,021	36,452,248				36,471,269
Proceeds from exercise of options	0
Change in Ownership in Subsidiary	0			(135,887)				(135,887)	135,887
Ending Balance (in shares) at Dec. 31, 2015		10,000	56,733,012
Ending Balance at Dec. 31, 2015	$ 23,283,824	$ 100	$ 56,733	$ 396,496,341	$ 486	$ (372,132,490)	$ (707,637)	$ 23,713,533	$ (429,709)

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (81,010,501)	$ (55,466,246)	$ (39,485,334)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock, stock options and warrants issued as payment for compensation, services rendered	9,750,110	11,209,542	6,838,559
Depreciation and amortization	2,686,779	2,186,949	1,605,608
Changes in fair value of derivative liability	0	(23,175)	(77,981)
Changes in acquisition-related contingent consideration	(18,260,000)	(3,080,000)	1,900,000
Impairment of Intangible Assets, Finite-lived	62,273,336	0	0
Bad debt (recovery) expense	0	(6,467)	(234,225)
Deferred income taxes	(17,243,528)	(104,202)	780,104
Amortization/Accretion on Marketable Securities	95,095	51,517	0
Changes in operating assets and liabilities:
Prepaids and other current assets	872,990	(2,768,062)	(758,798)
Accounts receivable	545,173	(1,198,844)	(573,005)
Deferred costs	(344,753)	(1,296,766)	(157,198)
Unearned revenues	1,011,104	2,517,520	348,260
Other assets	286,607	613,175	(204,422)
Accounts payable, accrued liabilities and other liabilities	79,257	469,821	2,916,739
Net cash used in operating activities	(39,258,331)	(46,895,238)	(27,101,693)
Cash flows from investing activities:
Cash Acquired from Acquisition	0	50,894	0
Payments to Acquire Marketable Securities	6,081,900	8,043,241	0
Proceeds from Sale and Maturity of Marketable Securities	13,066,014	913,000	0
Acquisition of property and equipment	3,185,737	3,657,352	2,691,471
Net cash provided by (used in) investing activities	3,798,377	(10,736,699)	(2,691,471)
Cash flows from financing activities:
Proceeds from exercise of options	0	271,008	150,658
Proceeds from exercise of warrants	0	1,720,725	3,028,241
Net proceeds from issuance of capital stock	36,471,269	16,710,645	58,736,165
Proceeds from long term debt	0	15,000,000	0
Debt issuance costs	0	(523,830)	0
Repayment of mortgage loan	0	3,236,721	201,754
Proceeds from notes payable	1,087,361	1,827,413	1,041,347
Repayment of notes payable	954,326	1,097,001	503,172
Payment for warrant inducement	0	0	62,014
Net cash provided by financing activities	36,604,304	30,672,239	62,189,471
Net (decrease) increase in cash and cash equivalents	1,144,350	(26,959,698)	32,396,307
Cash and cash equivalents at beginning of year	19,174,061	46,133,759	13,737,452
Cash and cash equivalents at end of year	20,318,411	19,174,061	46,133,759
Cash paid during the period for:
Interest	1,497,845	232,500	274,100
Taxes	0	0	0
Supplemental schedule of non-cash financing activities
Common stock and contingent consideration issued in merger	$ 0	$ 33,490,351	$ 0

The Business

12 Months Ended

Dec. 31, 2015

The Business [Abstract]

Nature of Operations

The Business

OVERVIEW

Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”), through its subsidiary, PCT, LLC, a Caladrius Company^TM("PCT"), is a leading provider of development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT has significant cell therapy-specific experience and expertise, an expansive list of noteworthy clients and significant revenue growth over the past two years. Notably, PCT and Hitachi Chemical Co. America, Ltd. and Hitachi Chemical Co., Ltd. ( collectively "Hitachi Chemical") recently entered into a strategic collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Caladrius leverages both its internal specialized cell therapy clinical development expertise and PCT’s prowess to select and develop early-stage cell therapy candidates with the intention of partnering these candidates post proof-of-concept in man to both generate value for our shareholders and to expand PCT’s client base. Our current product candidate, CLBS03, is a T regulatory cell (“Treg”) clinical Phase 2 therapy targeting adolescents with recent-onset type 1 diabetes.

Cell Therapy Development and Manufacturing

PCT is a leading cell therapy development and manufacturing provider (often called a contract development and manufacturing organization, or "CDMO"), specializing in cell and cell-based gene therapies. PCT offers high-quality development and manufacturing capabilities (e.g., current Good Manufacturing Practice (“cGMP”) manufacturing systems and facilities), quality systems, cell and tissue processing, logistics, storage and distribution) and engineering solutions (e.g., process and assay development, optimization and automation) to clients with therapeutic candidates at all stages of development. PCT produces clinical supplies and ultimately, intends also to produce commercial product for its clients. PCT has worked with over 100 clients and produced over 20,000 cell therapy products since it was founded seventeen years ago. PCT’s manufacturing services are designed to reduce the capital investment and time required by clients to advance their development programs compared to conducting the process development and manufacturing in-house. PCT has demonstrated regulatory expertise, including the support of over 50 U.S. and European Union ("EU") regulatory filings for clients, and expertise across multiple cell types and therapeutic applications, including immunotherapy (e.g. CAR-T therapies), neuro/endocrine therapies, hematopoietic replacement and tissue repair/regeneration. PCT offers a complete development pathway for its clients, with services supporting preclinical through commercial phase, all underpinned by timely process optimization and automation support. We currently operate facilities qualified under cGMPs in each of Allendale, New Jersey and Mountain View, California, including EU-compliant production capacity. On March 11, 2016, PCT entered into a strategic collaboration and license agreement with Hitachi Chemical to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. PCT is positioned to expand its capacity both in the United States and internationally, as needed. As the industry continues to mature and a growing number of cell therapy companies approach commercialization, we believe that PCT is well positioned to serve as an external manufacturing partner of choice for commercial-stage cell therapy companies.

CLBS03

We are developing strategically, through the utilization of or core development and manufacturing expertise, a product candidate that is an innovative therapy for type 1 diabetes mellitus ("TID"). This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of pediatric patients who are newly diagnosed with T1D. This program is based on the use of T regulatory cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells; the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the T effector cells to attack the body's own beneficial cells. In the case of T1D, there are currently no curative treatments, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of this technology in T1D demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect and an early indication of efficacy through the preservation of beta cell function. In the first quarter of 2016 we expect to commence patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate the safety and efficacy of our Treg product candidate, CLBS03, in adolescents with recent onset T1D. After the three-month follow-up of the first cohort of 18 patients, which is expected in early 2017, an initial safety analysis of the data and early analysis of immunological biomarkers will be undertaken. Satisfactory evaluation of the safety of the initial cohort as agreed by us, our independent Data Safety Monitoring Board and the U.S. Food and Drug Administration ("FDA") will then prompt the enrollment of the remaining 93 patients. A subsequent interim analysis of efficacy is planned after approximately 50% of patients reach the six-month follow-up milestone. We have entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D.

Additional Technology Platforms

Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing and partnering in order to continue their clinical development. These include platforms using tumor cell/dendritic cell technology for immuno-oncology and CD34 technology for ischemic repair. Both have the benefit of promising Phase 2 clinical data and are applicable to multiple indications. The immuno-oncology platform is based on our extensive intellectual property portfolio and includes CLBS20, a candidate for metastatic melanoma which was investigated in two Phase 2 trials and recently in a discontinued Phase 3 clinical trial. With respect to our ischemic repair platform, we are actively exploring a program to develop CLBS12 (a candidate for critical limb ischemia "CLI") under Japan's favorable regenerative medicine law and seeking to collaborate on CLBS 12 with development and/or manufacturing partners. In January 2016, we out-licensed our CD34 technology to SPS Cardio, LLC for chronic heart failure and acute myocardial infarction (candidate CLBS10) in India and other designated territories and non-major world markets outside the United States. Furthermore, a cell-derived dermatological product technology for topical skin application was out-licensed in February 2016 to AiVita Biomedical, Inc. ("AiVita"), which it intends to distribute through ALPHAEON Corporation. Finally, our Treg immune modulation platform has potential applications across multiple autoimmune and allergic diseases beyond TID for which we are exploring partnering opportunities, including steroid-resistant asthma, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, graft versus host disease, lupus and rheumatoid arthritis.

Our long term strategy focuses on advancing cell-based therapies to the market and assisting patients suffering from life-threatening medical conditions. Coupling our clinical development expertise with our process development and manufacturing capabilities, we believe we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on demonstration of proof-of-concept in man as well as process and manufacturing advancements.

Financial Information & Liquidity

On March 11, 2016, PCT entered into a global licensing, development and equity collaboration with Hitachi Chemical Co., LTD ("Hitachi Chemical"), a Japanese-based global conglomerate with a growing franchise in life sciences including regenerative medicine ("Hitachi Transaction"), and will receive an aggregate of $25.0 million in cash, of which $19.4 million was received in March 2016, and the remainder expected to be received before the end of 2016 (see Note 18). PCT will retain $10 million of the $25.0 million proceeds, and Caladrius will receive $15 million of the proceeds. Concurrent with the Hitachi Transaction, Caladrius will use $7.0 million of the proceeds to repay a portion of the outstanding loan with Oxford Finance (see Note 18). In addition to the Hitachi Transaction, we anticipate requiring additional capital in order to grow our PCT business, to fund the development of CLBS03, to fund other operating expenses, and to make principal and interest payments on our loan with Oxford Finance. To meet our short and long term liquidity needs, we currently expect to use existing cash and cash equivalents balances, our revenue generating activities and a variety of other means, including our common stock purchase agreements with Aspire Capital. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, option exercises, partnerships and/or collaborations and/or sale of assets. In addition, we will continue to seek as appropriate grants for scientific and clinical studies from various governmental agencies and foundations. We believe that the proceeds received in the Hitachi Transaction, along with our current cash, our revenue generating activities, and our access to funds under our agreement with Aspire Capital, will be sufficient to fund our operations for the next twelve months. While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available to us on acceptable terms, if at all. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay or discontinue the development of CLBS03, and/or the expansion of our business or raise funds on terms that we currently consider unfavorable.

In February 2016, we received written notification from NASDAQ informing us that our stock had traded under $1.00 for thirty (30) consecutive trading days, and that if it does not trade at or above $1.00 for ten (10) consecutive trading days during the next 180 days, our common stock would be delisted absent meeting other conditions for delaying delisting. We have 180 days after the date of the Nasdaq notification to regain compliance by maintaining a minimum closing bid price of $1.00 for ten consecutive trading days. If we are unable to regain compliance, NASDAQ will provide us with written notification that our common stock is subject to delisting. We may also elect to apply to transfer our common stock to the Nasdaq Capital Market if we satisfy all requirements, other than the minimum bid price requirement, for initial inclusion in this market. If we make such an election and our transfer application is approved, we will be eligible to regain compliance with the minimum closing bid price requirement until 180 days after the end of the first 180 day period. If, at the conclusion of either or both of the 180-day periods, we have not achieved compliance, we may appeal NASDAQ’s determination to delist our securities. We cannot assure you that we will be successful in regaining compliance with the Nasdaq Global Market listing requirements or that, if we choose to apply for transfer to the Nasdaq Capital Market, we would be successful in our application.

Basis of Presentation

The accompanying Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”). In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, include all normal and recurring adjustments considered necessary to present fairly the Company's financial position as of December 31, 2015 and 2014, and the results of its operations and its cash flows for the years ended December 31, 2015, 2014, and 2013.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining the fair values of goodwill for potential goodwill impairments for our reporting units, fair values of In-Process R&D assets, fair values of acquisition-related contingent considerations, useful lives of our tangible and intangible assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below. All intercompany activities have been eliminated in consolidation.



Entity	Percentage of Ownership	Location
Caladrius Biosciences, Inc.	100%	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
PCT, LLC, a Caladrius Company	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	97%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America

(1) As of December 31, 2015, Becton Dickinson's ownership interest in Athelos Corporation was 2.8%.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

We are subject to credit risk from our portfolio of cash and cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.

We are also subject to credit risk from our accounts receivable related to our services. The majority of our trade accounts receivable arises from services in the United States.

For the year ended December 31, 2015, four customers represented 17%, 14%, 10%, and 8% respectively, of total revenues recognized. As of December 31, 2015, four customers represented 60% of our accounts receivable.

Marketable Securities

The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.

Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.

Deferred Costs

The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's deferred costs represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.

Property, Plant, and Equipment

The cost of property, plant and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property, plant and equipment are as follows:



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Goodwill and Indefinite-Lived Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to in process research and development ("IPR&D") projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually, or at the time a triggering event is identified for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the IPR&D below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing an income approach model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s and IPR&D's estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with its accounting policy, the Company tested goodwill and IPR&D for impairment as of December 31, 2015, June 30, 2015, and December 31, 2014 for its two reporting units. As of June 30, 2015, the Company determined that IPR&D valued at $9.4 million was impaired (see Note 9). As of December 31, 2015, the Company determined that IPR&D valued at $34.3 million million and goodwill valued at $18.2 million were impaired (see Note 9). As of December 31, 2014, the Company concluded there was no goodwill impairment.

Definite-lived Intangible Assets

Definite-lived intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives. The Company reviews definite-lived intangibles assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. There were no impairments in 2015, 2014, and 2013.

Recognizing and Measuring Assets Acquired and Liabilities Assumed in Business Combinations at Fair Value

The Company accounts for acquired businesses using the purchase method of accounting, which requires that assets acquired and liabilities assumed be recorded at date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to IPR&D are included on the balance sheet . Intangible assets, including IPR&D assets upon successful completion of the project and approval of the product, are amortized on a straight-line basis to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected from future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the resulting timing and amount charged to, or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.

The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The resulting probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value at that time and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge to operating loss or income.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Loss Per Share

Basic loss per share is based on the weighted effect of all common shares issued and outstanding, and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share, which is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive in all periods presented due to losses incurred.

Income Taxes

The Company recognizes (a) the amount of taxes payable or refundable for the current year and (b) deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The Company continues to evaluate the accounting for uncertainty in tax positions at the end of each reporting period. The guidance requires companies to recognize in their financial statements the impact of a tax position if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The position ascertained inherently requires judgment and estimates by management. The Company recognizes interest and penalties as a component of income tax expense.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.

Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance.

Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.

Some client agreements include multiple elements, comprised of cell process development and cell manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the years ended December 31, 2015, 2014, and 2013, clinical services reimbursements were $3.4 million, $3.7 million, and $2.1 million, respectively.

Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

Research and Development Costs

Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.

To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.

New Accounting Pronouncement

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements - Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the provisions in this ASU should be followed to determine whether to disclose information about the relevant conditions and events. The ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the adoption of this ASU and its impact on the consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for us beginning in our first quarter of 2017. Early adoption is permitted. We do not expect this adoption to have a material impact on our financial statements.

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). The ASU improves on the classification of deferred taxes on the balance sheet by eliminating the current requirement. The current requirement presents deferred tax liabilities and assets as current and noncurrent in a classified balance sheet or statement of financial position. Under the ASU, organizations will now be required to classify all deferred tax assets and liabilities as noncurrent. The amendments apply to all organizations that present a classified balance sheet. For public companies, these amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.

In February 2016, the FASB issued ASU No. 2016-02 “Leases” (“ASU 2016-02”), which is effective for the fiscal years beginning after December 15, 2018. ASU 2016-02 requires entities to report a right of use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. The adoption of this standard, is not expected to have a material impact on the Company’s consolidated financial statements.

Acquisitions Acquisitions (Notes)

12 Months Ended

Dec. 31, 2015

Identified Assets Acquired [Abstract]

Mergers, Acquisitions and Dispositions Disclosures [Text Block]

Acquisition

On May 8, 2014, the Company closed (the “Closing”) its acquisition of CSC (the “CSC Acquisition”), pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among the Company and its acquisition subsidiaries (collectively, "Subco"), CSC, and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”). At Closing, Fortis Advisors LLC succeeded to the duties of the CSC Representative pursuant to the Merger Agreement. Pursuant to the Merger Agreement, on the Closing Date, Subco was merged with CSC (the “Merger”), with Subco surviving the Merger as a wholly-owned subsidiary of the Company. At Closing, Subco changed its legal name to NeoStem Oncology, LLC.

Aggregate Merger Consideration

Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (CSC Common Stock) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (CSC Options) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):

(1)An aggregate of 5,329,593 shares of our common stock (subject to payment of nominal cash in lieu of fractional shares) (the “Closing Merger Consideration”); and

(2)if payable after the Closing, certain payments in an amount of up to $90 million in the aggregate, payable in shares of the Company's Common Stock or cash, in the Company’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC Acquisition (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).

The fair value of the net assets acquired in the CSC Acquisition was $19.4 million. The fair value of the consideration paid by the Company was valued at $33.5 million, resulting in the recognition of goodwill in the amount of $14.1 million. The consideration paid was comprised of equity issued and milestone payments. The fair value of the equity issued by the Company was valued at $21.6 million. The fair value of the milestone payments was valued at $11.9 million, and is contingent on the achievement of certain milestones associated with the future development of the acquired programs. Such contingent consideration has been classified as a liability and will be subject to remeasurement at the end of each reporting period.

The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
	$	33,491

The total cost of the acquisition has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. The final allocation was completed during the measurement period which was one year from the date of acquisition.

Pro Forma Financial Information (unaudited)

The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the acquisition of CSC had occurred on January 1, 2013 (in thousands, except per share amounts):



	Twelve Months Ended December 31, 2014						Twelve Months Ended December 31, 2013
	(As Reported)			(Proforma -Unaudited)			(As Reported)			(Proforma -Unaudited)
Revenues	$	17,939		$	18,649		$	14,668		$	15,471
Net loss	$	(55,467	)	$	(57,964	)	$	(39,485	)	$	(44,790	)
Net loss attributable to Caladrius	$	(54,873	)	$	(57,371	)	$	(38,981	)	$	(44,286	)
Net loss per share attributable to Caladrius	$	(1.68	)	$	(1.51	)	$	(1.90	)	$	(1.71	)

The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the acquisition of CSC had been consummated on January 1, 2013, nor are they indicative of future results.

Availabe-for-Sale-Securities Available-for-Sale-Securities (Notes)

12 Months Ended

Dec. 31, 2015

Available-for-sale Securities [Abstract]

Cash, Cash Equivalents, and Marketable Securities [Text Block]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	December 31, 2015								December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	249.0	$	—	$	—	$	249.0	$	249.0	$	—	$	—	$	249.0
Corporate debt securities	1,047.2		—		—		1,047.2		—		—		—		—
Money market funds	837.7		—		—		837.7		12,791.9		—		—		12,791.9
Municipal debt securities	4,740.9		0.8		—		4,741.7		9,317.3		1.3		—		9,318.6
Total	$	6,874.8	$	0.8	$	—	$	6,875.6	$	22,358.2	$	1.3	$	—	$	22,359.5

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	December 31, 2015		December 31, 2014
Cash and cash equivalents	$	6,875.6	$	15,279.4
Marketable securities	—		7,080.1
Total	$	6,875.6	$	22,359.5

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	December 31, 2015
	Amortized Cost		Estimated Fair Value
Less than one year	$	6,874.8	$	6,875.6
Greater than one year	—		—
Total	$	6,874.8	$	6,875.6

Deferred Costs	12 Months Ended
Deferred Costs	Dec. 31, 2015
Inventories [Abstract]
Inventory Disclosure [Text Block]	Deferred Costs Deferred costs representing work in process for costs incurred on process development contracts that have not been completed, were $2.9 million and $2.6 million as of December 31, 2015 and December 31, 2014, respectively. The Company also has deferred revenue of approximately $4.9 million and $3.9 million of progress billings received as of December 31, 2015 and December 31, 2014, respectively, related to these contracts.

Property, Plant & Equipment

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Property, Plant and Equipment

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2015			2014
Building and improvements	$	11,478.6		$	11,298.7
Machinery and equipment	68.3			68.3
Lab equipment	7,461.2			6,324.7
Furniture and fixtures	2,320.9			1,166.3
Software	445.7			312.4
Leasehold improvements	2,831.5			2,219.6
Property, plant and equipment, gross	24,606.2			21,390.0
Accumulated depreciation	(7,541.4		)	(5,429.3		)
Property, plant and equipment, net	$	17,064.8		$	15,960.7

The Company’s results included depreciation expense of approximately $2.1 million, $1.6 million and $1.0 million for the years ended December 31, 2015, 2014, and 2013, respectively.

Loss Per Share

12 Months Ended

Dec. 31, 2015

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the years ended December 31, 2015, 2014, and 2013 the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive in the periods presented. At December 31, 2015, 2014, and 2013 the Company excluded the following potentially dilutive securities:



	December 31,
	2015	2014	2013
Stock Options	6,663,270	4,427,276	2,932,191
Warrants	3,214,033	3,550,956	4,898,266
Restricted Shares	202,776	280,481	78,500

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At December 31, 2015, 2014, and 2013 the Company excluded the following potentially dilutive securities:



	December 31,
	2015	2014	2013
Stock Options	6,663,270	4,427,276	2,932,191
Warrants	3,214,033	3,550,956	4,898,266
Restricted Shares	202,776	280,481	78,500

Fair Value Measurements

12 Months Ended

Dec. 31, 2015

Fair Value Measurements [Abstract]

Fair Value Measurements [Text Block]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company classifies the fair value of the warrant derivative liabilities as level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations.

The Company classifies the fair value of contingent consideration obligations as level 3 inputs. The Company has recognized contingent consideration obligations related to the following:

•

In October 2011, in connection with the acquisition (the "Amorcyte Acquisition") of Amorcyte, LLC ("Amorcyte"), contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate CLBS10 (in the event of and following the date of first commercial sale of CLBS10, a CD34 therapy), provided that in the event the Company sublicenses CLBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that the Company will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). As of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE-AMI Phase 2 clinical study for CLBS10, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, the Company determined that it will not pursue further development of CLBS10. As a result, the Amorcyte Acquisition contingent consideration fair value decreased from $5.5 million as of December 31, 2014 to $0 as of June 30, 2015, since the contingent consideration is based solely on future revenues of CLBS10. The change in estimated fair value has been recorded in other expense (income), net in our consolidated statement of operations.

•

In May 2014, in connection with the CSC Acquisition, contingent consideration obligations were recognized relating to milestone payments of up to $90 million, based on the achievement of certain milestones associated with the future development of the acquired programs, including CLBS20, a Phase 3 clinical study as a monotherapy for treatment of recurrent Stage III or Stage IV metastatic melanoma. As of December 31, 2015, the Company determined that the treatment paradigm in metastatic melanoma was transformed during the course of 2015 by the accelerating adoption of multiple immune checkpoint inhibitors used as monotherapy and in combination treatments. These new drugs have significantly improved outcomes in metastatic melanoma and therefore have altered the opportunity for a monotherapy such as CLBS20 in a landscape that is quickly converting to combination therapies, and as a result, the Company discontinued the ongoing CLBS20 Phase 3 clinical study. As a result, the CSC Acquisition contingent consideration fair value decreased from $12.8 million as of December 31, 2014 to $0 as of December 31, 2015. The change in estimated fair value has been recorded in other expenses in our consolidated statement of operations.

The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015, and December 31, 2014 (in thousands):



	December 31, 2015								December 31, 2014
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0
	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0

Liabilities:
Contingent consideration	—		—		—		—		—		—		18,260.0		18,260.0
	$	—	$	—	$	—	$	—	$	—	$	—	$	18,260.0	$	18,260.0

There were no transfers of financial instruments to or from Levels 1, 2 or 3 during the periods presented. For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2015 by type of instrument (in thousands):



	Year Ended
	December 31, 2015
	Contingent Consideration			Total
Beginning liability balance	$	18,260.0		$	18,260.0
Change in fair value recorded in operations	(18,260.0		)	(18,260.0		)
Ending liability balance	$	—		$	—

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, and accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2015

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The following table summarizes the changes in the carrying amount of goodwill (in thousands):



	Total
Balance as of December 31, 2014	$	25,209.3
Goodwill impairment	(18,196.0		)
Balance as of December 31, 2015	$	7,013.3

Goodwill impairment of $18.2 million is based on the Company's annual review for goodwill impairment as of December 31, 2015, and related to the Company's Research and Development reporting unit. The impairment is directly attributable to the Company's decision to discontinue its CLBS20 Phase 3 study. The Company evaluated whether goodwill was impaired in the Research and Development reporting unit as of June 30, 2015 in connection with its decision to no longer pursue further development of CLBS10, and concluded there was no goodwill impairment. The remaining goodwill is solely related to the PCT reporting unit.

The Company's intangible assets and related accumulated amortization as of December 31, 2015 and December 31, 2014 consisted of the following (in thousands):



		December 31, 2015							December 31, 2014
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(495.1	)	$	504.9	$	1,000.0	$	(395.1	)	$	604.9
Manufacturing technology	10 years	3,900.0		(1,930.9		)	1,969.1		3,900.0		(1,540.9		)	2,359.1
Tradename	10 years	800.0		(396.1		)	403.9		800.0		(316.1		)	483.9
In process R&D	Indefinite	—		—			—		43,690.0		—			43,690.0
Patent rights	19 years	—		—			—		669.0		(246.5		)	422.5
Total Intangible Assets		$	5,700.0	$	(2,822.1	)	$	2,877.9	$	50,059.0	$	(2,498.6	)	$	47,560.4

The Company’s IPR&D programs were acquired in the Amorcyte Acquisition (CD34 technology) and CSC Acquisition (tumor cell/dendritic cell technology).

•

CD34 Technology: The Company determined as of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE-AMI Phase 2 clinical study, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, that it will not pursue further development of CLBS10 for the acute myocardial infarction indication upon completion of the ongoing PreSERVE-AMI Phase 2 clinical study. However, it intends to explore other potential and more commercially viable indications of chronic heart failure and/or critical limb ischemia for its CD34 cell technology platform. These other indications are early stage opportunities, and would require external funding and/or partnerships to proceed to the next step in clinical development. As a result, and given the early stage and funding constraints of these other potential opportunities, the Company determined that IPR&D valued at $9.4 million was fully impaired as of June 30, 2015.

•

Tumor Cell/Dendritic Cell Technology: In May 2014, in connection with the CSC Acquisition, the Company acquired CLBS20, a Phase 3 clinical study as a monotherapy for treatment of recurrent Stage III or Stage IV metastatic melanoma.The Company determined as of December 31, 2015, that the treatment paradigm in metastatic melanoma was transformed during the course of 2015 by the accelerating adoption of multiple immune checkpoint inhibitors used as monotherapy and in combination treatments. These new drugs have significantly improved outcomes in metastatic melanoma and therefore have altered the opportunity for a monotherapy such as CLBS20 in a landscape that is quickly converting to combination therapies, and as a result, the Company discontinued the ongoing CLBS20 Phase 3 clinical study. As a result, given the changing competitive landscape and funding constraints of advancing this program, and a thorough evaluation of these factors by the Company's management in the fourth quarter of 2015, the Company determined that IPR&D valued at $34.3 million was fully impaired as of December 31, 2015.

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Year Ended December 31,
	2015		2014		2013
Cost of revenue	$	309.1	$	316.8	$	390.0
Research and development	116.1		108.4		35.2
Selling, general and administrative	180.0		180.0		180.0
Total	$	605.2	$	605.2	$	605.2

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2016	$	570.0
2017	570.0
2018	570.0
2019	570.0
2020	570.0
Thereafter	27.9
	$	2,877.9

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Liabilities

12 Months Ended

Dec. 31, 2015

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

Accrued liabilities were as follow (in thousands):



	December 31,
	2015		2014
Salaries, employee benefits and related taxes	$	2,771.2	$	2,807.2
Professional fees	480.7		495.4
Other	2,946.5		1,020.3
	$	6,198.4	$	4,322.9

Debt

12 Months Ended

Dec. 31, 2015

Debt [Abstract]

Debt Disclosure [Text Block]

Debt

Notes Payable

As of December 31, 2015 and December 31, 2014, the Company had notes payable of approximately $1.8 million and $1.6 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.

Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender disbursed $15.0 million (the “Loan”). After repayment of all outstanding amounts due under two loans from TD Bank, N.A. in the amount of approximately $3.1 million, and deductions for debt offering/issuance costs and interim period interest, the net proceeds from Loan were $11.3 million. The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Loan using the effective interest rate method. The proceeds from the Loan may be used to satisfy the Company’s future working capital needs, including the development of its cell therapy product candidates.

The Company has been making interest only payments on the outstanding amount of Loan on a monthly basis at a rate of 8.50% per annum. On April 29, 2015, with the Company's announcement that the first patient in the Intus Study had been randomized, the interest-only payment period on the Loan was extended from October 1, 2015 to April 1, 2016, which was in accordance with the Loan and Security Agreement. In March 2016, the interest-only payment period was extended through January 1, 2017 (see Note 18). Commencing on January 1, 2017, the Company will make 21 consecutive monthly payments of principal and interest. The Loan matures on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Loan. The final payment fee will be amortized to interest expense throughout the life of the Loan using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with Loan.

Under the Loan and Security Agreement and a related mortgage, the Company granted to Lender a security interest in all of the Company’s real property and personal property now owned or hereafter acquired, excluding intellectual property, and certain other assets and exemptions. The Company also entered into a Mortgage and Absolute Assignment of Leases and Rents (the "Mortgage"). The Company also granted Lender a security interest in the shares of the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of its business or property; and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated with the Loan and Security Agreement. As of December 31, 2015, the Company was in compliance with all covenants under the Loan and Security Agreement.

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement are as follows:



Years Ending December 31,	(in millions)
2016	$	5.3
2017	6.7
2018	6.2
Total	$	18.2

During the years ended December 31, 2015 and 2014, the Company recognized $1.3 million and $0.3 million of interest expense related to the Loan and Security Agreement.

Shareholders' Equity

12 Months Ended

Dec. 31, 2015

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Stockholders' Equity

Equity Plans

The Company's 2015 Equity Compensation Plan (the "2015 Equity Plan") was adopted by the stockholders of the Company on July 14, 2015, with 4,400,000 shares initially reserved for future awards under the 2015 Equity Plan (as adjusted in the manner described below, the “Share Reserve”). These shares will be available for issuance pursuant non-qualified stock options, incentive stock options , stock appreciation rights, restricted stock, restricted stock units, unrestricted shares, deferred share units, or other kinds of equity based compensation awards. Concurrent with the adoption of the 2015 Equity Plan, no future awards will occur under the 2009 Amended and Restated Equity Compensation Plan (the “2009 Plan”). The 2015 Equity Plan’s initial reserve of shares will automatically increase for 10 years, on each January 1^st beginning with 2016, by a number of shares equal to the lesser of (i) four percent (4%) of the total number of our shares outstanding on December 31^st of the preceding calendar year, (ii) such lesser number as the 2015 Plan’s administrator may earlier designate in writing, and (iii) 176,000 shares, which equals four percent (4%) of the initial reserve of 4,400,000 shares. In addition, the Share Reserve will include shares that are currently subject to awards under our 2009 Equity Plan but that are not issued due to their forfeiture, cancellation, or other settlement.

The 2009 Equity Plan was originally adopted by the stockholders of the Company on May 8, 2009. On October 29, 2009, the stockholders of the Company approved an amendment to the 2009 Equity Plan to increase the number of shares of common stock available for issuance thereunder from 380,000 to 975,000. At the 2010 Annual Meeting of Stockholders of the Company held on June 2, 2010, the stockholders approved an amendment to increase this number to 1,375,000. At a Special Meeting of Stockholders of the Company held on January 18, 2011, the stockholders approved an amendment to increase this number to 1,775,000. At the 2011 Annual Meeting of Stockholders of the Company held on October 14, 2011, the stockholders approved an amendment to increase this number to 2,375,000. At the 2012 Annual Meeting of Stockholders of the Company held on October 5, 2012, the stockholders approved an amendment to (i) merge the 570,000 shares reserved for issuance under the Company's 2009 Non-U.S. Based Equity Compensation Plan (the "Non-U.S. Plan") with and into the 2009 Equity Plan, and (ii) increase by 450,000 the aggregate number of shares authorized for issuance under the 2009 Equity Plan (the “2009 Amended & Restated Equity Plan”). At the Company's 2013 Annual Meeting held October 3, 2013, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 5,995,000. At the Company's 2014 Annual Meeting held October 6, 2014, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 8,995,000.

The Company's 2003 Equity Participation Plan (the “2003 Equity Plan”) expired in 2013 and accordingly, equity awards under the 2003 Equity Plan can no longer be issued. The Company's 2009 Equity Compensation Plan (the “2009 Equity Plan”) makes up to 8,995,000 shares of common stock of the Company (as of December 31, 2015) available for issuance to employees, consultants, advisors and directors of the Company and its subsidiaries pursuant to incentive or non-statutory stock options, restricted and unrestricted stock awards and stock appreciation rights.

All stock options under the 2003 Equity Plan and 2009 Equity Plan were granted and the 2015 Equity Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a consultant, employee or director of the Company.

The number of remaining shares authorized to be issued under the various equity plans are as follows as of December 31, 2015:



	2003 Equity Plan		2009 Equity Plan		2015 Equity Plan
Shares Authorized for Issuance	250,000		8,995,000		4,400,000
Outstanding Stock Options	(108,745	)	(6,113,425	)	(441,100	)
Exercised Stock Options	(9,250	)	(80,856	)	—
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(1,601,033	)	—
Shares Expired	(43,012	)	—		—
Total common shares remaining to be issued under the Equity Plans	—		1,199,686		3,958,900

The Company adopted an employee stock purchase plan effective January 1, 2013, and authorized 500,000 shares under the plan. The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's Common Stock on the Exercise Date of such Offering Period, whichever is lower. During the year ended December 31, 2015, 133,939shares were issued under the employee stock purchase plan. At December 31, 2015, the Company had 300,620 shares of the Company's common stock available for future grant in connection with this plan.

Equity Issuances

June 2015 Public Offering

In June 2015, the Company completed an underwritten offering of 12.5 million shares of the Company's common stock, at a public offering price of $2.00 per share. The underwriters also exercised their entire over-allotment option of 1.875 million shares. The Company received gross proceeds of $28.8 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

Aspire Purchase Agreements

In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions and Nasdaq rules, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 11.0 million shares, unless stockholder approval is obtained or certain minimum sale price levels are reached) of the Company's common stock over a 24-month term. As consideration for entering into the Purchase Agreement, the Company issued 842,696 shares of its common stock to Aspire Capital. During the years ended December 31, 2015, the Company issued 200,000 shares of common stock under the Purchase Agreement with Aspire for gross proceeds of $0.3 million.

Under the Purchase Agreement, at the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price, trading volume and conditions, including Nasdaq trading requirements, are met. The purchase price for the shares of common stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements. We have filed a registration statement with the SEC and a related prospectus supplement that covers the offering of shares of our common stock subject to the Purchase Agreement, and therefore can initiate sales to Aspire at any time.

We are party to two existing agreements with Aspire Capital (the "May 2015 Purchase Agreement" and the "March 2014 Purchase Agreement", or collectively, the "Previous Purchase Agreements"). The registration statement we previously filed with the SEC to cover offerings of shares of our common stock subject to the previous Purchase Agreements has expired, and we have not, and currently have no intention to include such shares in a registration statement filed with the SEC. Unless and until we include such shares in a registration statement filed with the SEC, we are unable to initiate sales to Aspire under the Previous Purchase Agreements.

Under the May 2015 Purchase Agreement, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares. As consideration for entering into the May 2015 Purchase Agreement, the Company issued 364,837 shares of its common stock to Aspire Capital. The Company has not issued any additional shares under the May 2015 Purchase Agreement. Under the March 2014 Purchase Agreement, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares. As consideration for entering into the March 2014 Purchase Agreement, the Company issued 150,000 shares of its common stock to Aspire Capital. During the years ended December 31, 2015, the Company issued 3.0 million shares of common stock under the March 2014 Purchase Agreement with Aspire for gross proceeds of $9.4 million. Overall, the Company issued 5.1 million shares under the March 2014 Purchase Agreement for gross proceeds of $20.3 million.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2015:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0

Changes during the Year:
Granted	3,414,388		$	3.01				—		$	—
Exercised	—		$	—				—		$	—
Forfeited	(437,770	)	$	4.92				—		$	—
Expired	(740,372	)	$	7.83				(336,923	)	$	17.91
Outstanding at December 31, 2015	6,663,480		$	6.46	6.88	$	0.1	3,214,033		$	13.72	1.26	$	—
Vested at December 31, 2015 or expected to vest in the future	6,663,480		$	6.58	6.79	$	0.1	3,214,033		$	13.72	1.26	$	—
Exercisable at December 31, 2015	4,837,711		$	7.46	6.12	$	—	3,214,033		$	13.72	1.26	$	—

The total intrinsic value of stock options exercised during the years ended December 31, 2015 and December 31, 2014 was $0 and $61,641, respectively.

During the years ended December 31, 2015 and 2014, the Company did not issue warrants for services.

Restricted Stock

During the years ended December 31, 2015 and 2014, the Company issued restricted stock for services as follows ($ in thousands, except share data):




	2015		2014
Number of Restricted Stock Issued	928,000		917,907
Value of Restricted Stock Issued	$	2,488.6	$	4,996.3

The weighted average estimated fair value of restricted stock issued for services in the years ended December 31, 2015 and 2014 was $2.68 and $5.44 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Share-Based Compensation (Notes)

12 Months Ended

Dec. 31, 2015

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the years ended December 31, 2015, 2014 , and 2013 ($ in thousands):



	Year Ended December 31,
	2015		2014		2013
Cost of revenues	$	545.3	$	494.2	$	314.0
Research and development	1,811.5		2,058.2		822.2
Selling, general and administrative	7,393.3		8,657.1		5,702.5
Total share-based compensation expense	$	9,750.1	$	11,209.5	$	6,838.7

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2015 were as follows ($ in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	3,078.6	$	—	$	332.0
Expected weighted-average period in years of compensation cost to be recognized	3.17		0.00		1.95

Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2015, 2014, and 2013 were as follows ($ in thousands):



	Stock Options						Warrants
	Year Ended December 31,						Year Ended December 31,
	2015		2014		2013		2015		2014		2013
Total fair value of shares vested	$	6,133.0	$	5,387.1	$	3,375.7	$	—	$	9.6	$	129.0
Weighted average estimated fair value of shares granted	1.95		4.56		4.29		—		—		3.71

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

The range of assumptions made in calculating the fair values of stock options and warrants was as follow:



	Stock Options			Warrants
	Year Ended December 31,			Year Ended December 31,
	2015	2014	2013	2015	2014	2013
Expected term - minimum (in years)	2	0	1	0	3	2
Expected term - maximum (in years)	10	10	10	0	3	5
Expected volatility - minimum	71%	62%	61%	—	66%	73%
Expected volatility - maximum	75%	77%	79%	—	66%	79%
Weighted Average volatility	74%	74%	83%	—	74%	82%
Expected dividend yield	—	—	—	—	—	—
Risk-free interest rate - minimum	1.19%	0.12%	0.13%	—	0.79%	0.32%
Risk-free interest rate - maximum	2.14%	3.00%	2.67%	—	0.79%	1.73%

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Income Tax Disclosure [Text Block]

Income Taxes

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):



	Years Ended December 31,
	2015			2014			2013
United States	$	(98,254.0	)	$	(55,570.4	)	$	(38,705.2	)

	$	(98,254.0	)	$	(55,570.4	)	$	(38,705.2	)

The provision (benefit) for income taxes was as follows ($ in thousands):



		Years Ended December 31,
		2015			2014			2013
Current
	U.S. Federal	$	—		$	—		$	—
	State and local	—			—			—
		$	—		$	—		$	—
Deferred
	U.S. Federal	$	(14,695.5	)	$	159.0		$	476.9
	State and local	(2,548.0		)	(263.2		)	303.2
		$	(17,243.5	)	$	(104.2	)	$	780.1
Total
	U.S. Federal	$	(14,695.5	)	$	159.0		$	476.9
	State and local	(2,548.0		)	(263.2		)	303.2
		$	(17,243.5	)	$	(104.2	)	$	780.1

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 34% to income before income taxes as a result of the following ($ in thousands):



	Years Ended December 31,
	2015			2014			2013
U.S. Federal benefit at statutory rate	$	(33,406.4	)	$	(18,894.0	)	$	(13,159.8	)
State and local benefit net of U.S. federal tax	(4,926.9		)	(3,435.0		)	(3,430.9		)
Permanent non deductible expenses for U.S. taxes	706.4			1,094.6			1,798.2
True-up of prior year net operating loss	(556.5		)	(25.5		)	(91.4		)
Return to actual	—			—			(3,822.9		)
Effect of change in deferred tax rate	1.3			1,075.7			(1,094.8		)
Valuation allowance for deferred tax assets	20,938.6			20,080.0			20,581.7
Tax provision	$	(17,243.5	)	$	(104.2	)	$	780.1

Deferred income taxes at December 31, 2015, 2014 and 2013 consist of the following ($ in thousands):



	December 31,
	2015			2014			2013
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	86,537.8		$	69,047.0		$	25,727.7
Deferred revenue	—			—			23.1
Deferred rent	11.1			(7.8		)	15.2
Share-based compensation	12,764.3			9,577.2			5,466.7
Intangibles	899.7			715.1			287.3
Accumulated depreciation	—			—			348.7
Charitable contributions	423.3			409.8			391.8
Bad debt provision	297.4			296.9			239.7
Capital loss carry-forward	6,973.0			6,925.1			6,644.5
Other	652.1			609.7			—
Deferred tax assets prior to tax credit carryovers	108,558.7			87,573.0			39,144.7

Deferred Tax Liabilities:
Accumulated depreciation	$	(66.0	)	$	(18.8	)	$	—
Intangible and indefinite lived assets	(932.7		)	(18,176.3		)	(3,599.1		)
Deferred tax liabilities	(998.7		)	(18,195.1		)	(3,599.1		)
	107,560.0			69,377.9			35,545.6
Valuation reserve	(108,492.7		)	(87,554.1		)	(39,144.7		)
Net deferred tax liability	$	(932.7	)	$	(18,176.2	)	$	(3,599.1	)

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

As of December 31, 2015 and 2014, the Company had approximately $221.5 million and $177.2 million, respectively of Federal NOLs available to offset future taxable income expiring from 2026 through 2035. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2035.

The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

As of December 31, 2015, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

The Federal tax returns are currently being audited for the years 2012 and 2013. For years prior to 2011 the federal statute of limitations is closed. Most of the remaining states remain open to examination for a period of 3 to 4 years from date of filing. The Company files tax returns in all of the foreign jurisdictions that it has a permanent establishment and the tax filings remain subject to examination for 4 to 5 years.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	Related Party Transactions In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 11). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, including Dr. Pecora, had been released as guarantors of the Second Mortgage Loan, and Caladrius had become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by Caladrius to the Lender. Dr. Pecora, currently serves as a Caladrius director.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

We entered into an assignment agreement with an unaffiliated third party, effective February 19, 2015, for general office space located in Basking Ridge, NJ. This property is used as the Company's corporate headquarters. The space is approximately 18,000 rentable square feet. The base monthly rent is currently $31,875and the lease term ends July 31, 2020. In addition, there are two (2) five (5) year renewal options. In connection with the assumption of the lease, the third party (a) conveyed its rights in various scheduled furniture and equipment and (b) paid the Company approximately $580,000. The amount paid to the Company included a security deposit of approximately $115,000. The Company also leases facilities in New York, NY, Irvine, CA, and Mountain View, CA, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2021.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2015 are as follows (in thousands):



Years ended	Operating Leases
2016	2,062.0
2017	1,863.8
2018	1,034.7
2019	989.4
2020 and thereafter	960.2
Total minimum lease payments	$	6,910.1

Expense incurred under operating leases were approximately $1.7 million , $1.3 million , and $1.1 million for the years ended December 31, 2015, 2014, and 2013, respectively.

Contingencies

We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: Trex Study) to evaluate the safety and efficacy of the Company’s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment is expected to commence as early as the first quarter of 2016. We will be initially responsible for the supply of all study drug to the first 18 enrolled patients upon commencement of the study.

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Quarterly Financial Data (Notes)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

Quarterly Financial Data (unaudited)

The tables below summarize the Company's unaudited quarterly operating results for the years ended December 31, 2015 and 2014, respectively.



	Three Months Ended
(in thousands, except per share data)	March 31, 2015			June 30, 2015			September 30, 2015			December 31, 2015
Revenues	$	3,172		$	5,867		$	5,888		$	7,560
Total operating costs and expenses	$	21,260		$	31,536		$	16,271		$	67,269
Net loss	$	(19,231	)	$	(17,158	)	$	(11,393	)	$	(33,228	)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$	(19,187	)	$	(17,126	)	$	(11,376	)	$	(33,197	)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$	(0.51	)	$	(0.38	)	$	(0.21	)	$	(0.59	)



	Three Months Ended
(in thousands, except per share data)	March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
Revenues	$	4,056		$	4,489		$	4,118		$	5,276
Total operating costs and expenses	$	17,555		$	16,919		$	20,376		$	20,830
Net loss	$	(13,830	)	$	(12,769	)	$	(17,177	)	$	(11,691	)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$	(13,682	)	$	(12,605	)	$	(16,974	)	$	(11,612	)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$	(0.49	)	$	(0.40	)	$	(0.48	)	$	(0.32	)

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Events Hitachi Transaction On March 11, 2016, PCT entered into a global collaboration that includes licensing, development and equity components with Hitachi Chemical Co., LTD ("Hitachi Chemical"), a Japanese-based global conglomerate with a growing franchise in life sciences including regenerative medicine ("Hitachi Transaction") to develop our PCT business outside of the U.S. This collaboration consists of an equity investment in, and a license agreement with, PCT. Under the equity investment agreement, Hitachi Chemical purchased a 19.9% membership interest in PCT for $19.4 million of which $15.0 million will be distributed to Caladrius from PCT and $4.4 million will remain at PCT, which will be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes. Caladrius remains the majority shareholder retaining an 80.1% ownership interest. PCT and Hitachi Chemical also entered into an exclusive license agreement for Asia pursuant to which PCT will receive $5.6 million from Hitachi Chemical in three fee driven payments throughout 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi Chemical with certain training and support. As additional consideration, Hitachi Chemical will pay PCT royalties on contract revenue generated in Asia for a minimum of 10 years. Lastly, as part of the transaction, PCT and Hitachi Chemical agreed to explore the possibility of pursuing a collaboration in cell therapy manufacture in Europe. Oxford Debt Repayment On March 11, 2016, upon execution of the Hitachi Transaction, the Company and Oxford Finance LLC entered into an amendment to the Loan and Security Agreement whereby (i) the Company paid $7.0 million to Oxford Finance LLC, comprised of principal, interest and early termination fees, (ii) the Company's subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Oxford Finance LLC's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance is extended until January 1 2017, and (v) in the event the Company receives gross proceeds from the sale or issuance of any equity securities or subordinated debt, or any partnership, licenses, collaboration, dividend, grant or asset sale through March 31, 2017, 20% of such proceeds will be paid to Oxford Finance LLC, up to a $3.0 million maximum. If 20% of such proceeds in aggregate is less than $3.0 million by March 31, 2017, then the Company will make a lump sum payment equal to the difference by March 31, 2017. Common Stock and Warrant Issuances On March 10, 2016, the Company entered into a securities purchase agreement with certain investors, pursuant to which Caladrius issued and sold in a private placement an aggregate of 1.4 million shares of common stock and a two-year warrant to purchase up to an aggregate of 1.4 million shares of Caladrius' common stock, at an exercise price of $1.00 per share. The unit purchase price for a share of Caladrius common stock and warrant to purchase one share of Caladrius common stock was $0.705 per unit, with $1 million of gross proceeds received by Caladrius.

The Business (Tables)

12 Months Ended

Dec. 31, 2015

The Business [Abstract]

Subsidiary



Entity	Percentage of Ownership	Location
Caladrius Biosciences, Inc.	100%	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
PCT, LLC, a Caladrius Company	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	97%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America

(1) As of December 31, 2015, Becton Dickinson's ownership interest in Athelos Corporation was 2.8%.

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Property, Plant and Equipment [Table Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2015			2014
Building and improvements	$	11,478.6		$	11,298.7
Machinery and equipment	68.3			68.3
Lab equipment	7,461.2			6,324.7
Furniture and fixtures	2,320.9			1,166.3
Software	445.7			312.4
Leasehold improvements	2,831.5			2,219.6
Property, plant and equipment, gross	24,606.2			21,390.0
Accumulated depreciation	(7,541.4		)	(5,429.3		)
Property, plant and equipment, net	$	17,064.8		$	15,960.7

Revenue Recognition, Policy [Policy Text Block]

Treasury Stock

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

Property, Plant and Equipment, Policy [Policy Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2015

Identified Assets Acquired [Abstract]

Business Acquisition, Pro Forma Information [Table Text Block]



	Twelve Months Ended December 31, 2014						Twelve Months Ended December 31, 2013
	(As Reported)			(Proforma -Unaudited)			(As Reported)			(Proforma -Unaudited)
Revenues	$	17,939		$	18,649		$	14,668		$	15,471
Net loss	$	(55,467	)	$	(57,964	)	$	(39,485	)	$	(44,790	)
Net loss attributable to Caladrius	$	(54,873	)	$	(57,371	)	$	(38,981	)	$	(44,286	)
Net loss per share attributable to Caladrius	$	(1.68	)	$	(1.51	)	$	(1.90	)	$	(1.71	)

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
	$	33,491

Availabe-for-Sale-Securities schedule of available-for-Sales (Tables)

12 Months Ended

Dec. 31, 2015

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	December 31, 2015								December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	249.0	$	—	$	—	$	249.0	$	249.0	$	—	$	—	$	249.0
Corporate debt securities	1,047.2		—		—		1,047.2		—		—		—		—
Money market funds	837.7		—		—		837.7		12,791.9		—		—		12,791.9
Municipal debt securities	4,740.9		0.8		—		4,741.7		9,317.3		1.3		—		9,318.6
Total	$	6,874.8	$	0.8	$	—	$	6,875.6	$	22,358.2	$	1.3	$	—	$	22,359.5

Marketable Securities [Table Text Block]



	December 31, 2015		December 31, 2014
Cash and cash equivalents	$	6,875.6	$	15,279.4
Marketable securities	—		7,080.1
Total	$	6,875.6	$	22,359.5

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	December 31, 2015
	Amortized Cost		Estimated Fair Value
Less than one year	$	6,874.8	$	6,875.6
Greater than one year	—		—
Total	$	6,874.8	$	6,875.6

Property, Plant & Equipment (Tables)

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2015			2014
Building and improvements	$	11,478.6		$	11,298.7
Machinery and equipment	68.3			68.3
Lab equipment	7,461.2			6,324.7
Furniture and fixtures	2,320.9			1,166.3
Software	445.7			312.4
Leasehold improvements	2,831.5			2,219.6
Property, plant and equipment, gross	24,606.2			21,390.0
Accumulated depreciation	(7,541.4		)	(5,429.3		)
Property, plant and equipment, net	$	17,064.8		$	15,960.7

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2015

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share



	December 31,
	2015	2014	2013
Stock Options	6,663,270	4,427,276	2,932,191
Warrants	3,214,033	3,550,956	4,898,266
Restricted Shares	202,776	280,481	78,500

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At December 31, 2015, 2014, and 2013 the Company excluded the following potentially dilutive securities:



	December 31,
	2015	2014	2013
Stock Options	6,663,270	4,427,276	2,932,191
Warrants	3,214,033	3,550,956	4,898,266
Restricted Shares	202,776	280,481	78,500

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2015

Fair Value Measurements [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]



	December 31, 2015								December 31, 2014
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0
	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0

Liabilities:
Contingent consideration	—		—		—		—		—		—		18,260.0		18,260.0
	$	—	$	—	$	—	$	—	$	—	$	—	$	18,260.0	$	18,260.0

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2015 by type of instrument (in thousands):



	Year Ended
	December 31, 2015
	Contingent Consideration			Total
Beginning liability balance	$	18,260.0		$	18,260.0
Change in fair value recorded in operations	(18,260.0		)	(18,260.0		)
Ending liability balance	$	—		$	—

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill [Table Text Block]

thousands):



	Total
Balance as of December 31, 2014	$	25,209.3
Goodwill impairment	(18,196.0		)
Balance as of December 31, 2015	$	7,013.3

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

s of December 31, 2015 and December 31, 2014 consisted of the following (in thousands):



		December 31, 2015							December 31, 2014
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(495.1	)	$	504.9	$	1,000.0	$	(395.1	)	$	604.9
Manufacturing technology	10 years	3,900.0		(1,930.9		)	1,969.1		3,900.0		(1,540.9		)	2,359.1
Tradename	10 years	800.0		(396.1		)	403.9		800.0		(316.1		)	483.9
In process R&D	Indefinite	—		—			—		43,690.0		—			43,690.0
Patent rights	19 years	—		—			—		669.0		(246.5		)	422.5
Total Intangible Assets		$	5,700.0	$	(2,822.1	)	$	2,877.9	$	50,059.0	$	(2,498.6	)	$	47,560.4

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Year Ended December 31,
	2015		2014		2013
Cost of revenue	$	309.1	$	316.8	$	390.0
Research and development	116.1		108.4		35.2
Selling, general and administrative	180.0		180.0		180.0
Total	$	605.2	$	605.2	$	605.2

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2016	$	570.0
2017	570.0
2018	570.0
2019	570.0
2020	570.0
Thereafter	27.9
	$	2,877.9

Accrued Liabilities Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities were as follow (in thousands):



	December 31,
	2015		2014
Salaries, employee benefits and related taxes	$	2,771.2	$	2,807.2
Professional fees	480.7		495.4
Other	2,946.5		1,020.3
	$	6,198.4	$	4,322.9

Debt Long term debt, maturities (Tables)

12 Months Ended

Dec. 31, 2015

Long-term Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]



Years Ending December 31,	(in millions)
2016	$	5.3
2017	6.7
2018	6.2
Total	$	18.2

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2015

Shareholders’ Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The number of remaining shares authorized to be issued under the various equity plans are as follows as of December 31, 2015:



	2003 Equity Plan		2009 Equity Plan		2015 Equity Plan
Shares Authorized for Issuance	250,000		8,995,000		4,400,000
Outstanding Stock Options	(108,745	)	(6,113,425	)	(441,100	)
Exercised Stock Options	(9,250	)	(80,856	)	—
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(1,601,033	)	—
Shares Expired	(43,012	)	—		—
Total common shares remaining to be issued under the Equity Plans	—		1,199,686		3,958,900

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2015:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0

Changes during the Year:
Granted	3,414,388		$	3.01				—		$	—
Exercised	—		$	—				—		$	—
Forfeited	(437,770	)	$	4.92				—		$	—
Expired	(740,372	)	$	7.83				(336,923	)	$	17.91
Outstanding at December 31, 2015	6,663,480		$	6.46	6.88	$	0.1	3,214,033		$	13.72	1.26	$	—
Vested at December 31, 2015 or expected to vest in the future	6,663,480		$	6.58	6.79	$	0.1	3,214,033		$	13.72	1.26	$	—
Exercisable at December 31, 2015	4,837,711		$	7.46	6.12	$	—	3,214,033		$	13.72	1.26	$	—

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2015, 2014 , and 2013 ($ in thousands):



	Year Ended December 31,
	2015		2014		2013
Cost of revenues	$	545.3	$	494.2	$	314.0
Research and development	1,811.5		2,058.2		822.2
Selling, general and administrative	7,393.3		8,657.1		5,702.5
Total share-based compensation expense	$	9,750.1	$	11,209.5	$	6,838.7

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

During the years ended December 31, 2015 and 2014, the Company did not issue warrants for services.

Restricted Stock [Table Text Block]

During the years ended December 31, 2015 and 2014, the Company issued restricted stock for services as follows ($ in thousands, except share data):




	2015		2014
Number of Restricted Stock Issued	928,000		917,907
Value of Restricted Stock Issued	$	2,488.6	$	4,996.3

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2015

Share-based Compensation [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2015:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0

Changes during the Year:
Granted	3,414,388		$	3.01				—		$	—
Exercised	—		$	—				—		$	—
Forfeited	(437,770	)	$	4.92				—		$	—
Expired	(740,372	)	$	7.83				(336,923	)	$	17.91
Outstanding at December 31, 2015	6,663,480		$	6.46	6.88	$	0.1	3,214,033		$	13.72	1.26	$	—
Vested at December 31, 2015 or expected to vest in the future	6,663,480		$	6.58	6.79	$	0.1	3,214,033		$	13.72	1.26	$	—
Exercisable at December 31, 2015	4,837,711		$	7.46	6.12	$	—	3,214,033		$	13.72	1.26	$	—

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2015, 2014 , and 2013 ($ in thousands):



	Year Ended December 31,
	2015		2014		2013
Cost of revenues	$	545.3	$	494.2	$	314.0
Research and development	1,811.5		2,058.2		822.2
Selling, general and administrative	7,393.3		8,657.1		5,702.5
Total share-based compensation expense	$	9,750.1	$	11,209.5	$	6,838.7

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	3,078.6	$	—	$	332.0
Expected weighted-average period in years of compensation cost to be recognized	3.17		0.00		1.95

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2015, 2014, and 2013 were as follows ($ in thousands):



	Stock Options						Warrants
	Year Ended December 31,						Year Ended December 31,
	2015		2014		2013		2015		2014		2013
Total fair value of shares vested	$	6,133.0	$	5,387.1	$	3,375.7	$	—	$	9.6	$	129.0
Weighted average estimated fair value of shares granted	1.95		4.56		4.29		—		—		3.71

Schedule of Range of Fair Value of Stock Options and Warrants [Table Text Block]

The range of assumptions made in calculating the fair values of stock options and warrants was as follow:



	Stock Options			Warrants
	Year Ended December 31,			Year Ended December 31,
	2015	2014	2013	2015	2014	2013
Expected term - minimum (in years)	2	0	1	0	3	2
Expected term - maximum (in years)	10	10	10	0	3	5
Expected volatility - minimum	71%	62%	61%	—	66%	73%
Expected volatility - maximum	75%	77%	79%	—	66%	79%
Weighted Average volatility	74%	74%	83%	—	74%	82%
Expected dividend yield	—	—	—	—	—	—
Risk-free interest rate - minimum	1.19%	0.12%	0.13%	—	0.79%	0.32%
Risk-free interest rate - maximum	2.14%	3.00%	2.67%	—	0.79%	1.73%

Income Taxes income taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]



	Years Ended December 31,
	2015			2014			2013
United States	$	(98,254.0	)	$	(55,570.4	)	$	(38,705.2	)

	$	(98,254.0	)	$	(55,570.4	)	$	(38,705.2	)

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The provision (benefit) for income taxes was as follows ($ in thousands):



		Years Ended December 31,
		2015			2014			2013
Current
	U.S. Federal	$	—		$	—		$	—
	State and local	—			—			—
		$	—		$	—		$	—
Deferred
	U.S. Federal	$	(14,695.5	)	$	159.0		$	476.9
	State and local	(2,548.0		)	(263.2		)	303.2
		$	(17,243.5	)	$	(104.2	)	$	780.1
Total
	U.S. Federal	$	(14,695.5	)	$	159.0		$	476.9
	State and local	(2,548.0		)	(263.2		)	303.2
		$	(17,243.5	)	$	(104.2	)	$	780.1

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 34% to income before income taxes as a result of the following ($ in thousands):



	Years Ended December 31,
	2015			2014			2013
U.S. Federal benefit at statutory rate	$	(33,406.4	)	$	(18,894.0	)	$	(13,159.8	)
State and local benefit net of U.S. federal tax	(4,926.9		)	(3,435.0		)	(3,430.9		)
Permanent non deductible expenses for U.S. taxes	706.4			1,094.6			1,798.2
True-up of prior year net operating loss	(556.5		)	(25.5		)	(91.4		)
Return to actual	—			—			(3,822.9		)
Effect of change in deferred tax rate	1.3			1,075.7			(1,094.8		)
Valuation allowance for deferred tax assets	20,938.6			20,080.0			20,581.7
Tax provision	$	(17,243.5	)	$	(104.2	)	$	780.1

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Deferred income taxes at December 31, 2015, 2014 and 2013 consist of the following ($ in thousands):



	December 31,
	2015			2014			2013
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	86,537.8		$	69,047.0		$	25,727.7
Deferred revenue	—			—			23.1
Deferred rent	11.1			(7.8		)	15.2
Share-based compensation	12,764.3			9,577.2			5,466.7
Intangibles	899.7			715.1			287.3
Accumulated depreciation	—			—			348.7
Charitable contributions	423.3			409.8			391.8
Bad debt provision	297.4			296.9			239.7
Capital loss carry-forward	6,973.0			6,925.1			6,644.5
Other	652.1			609.7			—
Deferred tax assets prior to tax credit carryovers	108,558.7			87,573.0			39,144.7

Deferred Tax Liabilities:
Accumulated depreciation	$	(66.0	)	$	(18.8	)	$	—
Intangible and indefinite lived assets	(932.7		)	(18,176.3		)	(3,599.1		)
Deferred tax liabilities	(998.7		)	(18,195.1		)	(3,599.1		)
	107,560.0			69,377.9			35,545.6
Valuation reserve	(108,492.7		)	(87,554.1		)	(39,144.7		)
Net deferred tax liability	$	(932.7	)	$	(18,176.2	)	$	(3,599.1	)

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2015 are as follows (in thousands):



Years ended	Operating Leases
2016	2,062.0
2017	1,863.8
2018	1,034.7
2019	989.4
2020 and thereafter	960.2
Total minimum lease payments	$	6,910.1

Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

respectively.



	Three Months Ended
(in thousands, except per share data)	March 31, 2015			June 30, 2015			September 30, 2015			December 31, 2015
Revenues	$	3,172		$	5,867		$	5,888		$	7,560
Total operating costs and expenses	$	21,260		$	31,536		$	16,271		$	67,269
Net loss	$	(19,231	)	$	(17,158	)	$	(11,393	)	$	(33,228	)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$	(19,187	)	$	(17,126	)	$	(11,376	)	$	(33,197	)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$	(0.51	)	$	(0.38	)	$	(0.21	)	$	(0.59	)



	Three Months Ended
(in thousands, except per share data)	March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
Revenues	$	4,056		$	4,489		$	4,118		$	5,276
Total operating costs and expenses	$	17,555		$	16,919		$	20,376		$	20,830
Net loss	$	(13,830	)	$	(12,769	)	$	(17,177	)	$	(11,691	)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$	(13,682	)	$	(12,605	)	$	(16,974	)	$	(11,612	)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$	(0.49	)	$	(0.40	)	$	(0.48	)	$	(0.32	)

The Business - Cell Therapy Development and Manufacturing (Details) - PCT Allendale, LLC [Member]	12 Months Ended
	Dec. 31, 2015 client product filing
Subsidiary or Equity Method Investee [Line Items]
Number of clients worked with (client) \| client	100
Number of products produced (product) \| product	20,000
Number of years since foundation	17 years
United States And European Union [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of supported regulatory filings \| filing	50

The Business - CLBS03 (Details)	12 Months Ended
The Business - CLBS03 (Details)	Dec. 31, 2015 patient cohort
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Interim efficacy analysis, percentage threshold	50.00%
Interim efficacy analysis, follow-up milestone period	6 years
The Sanford Project: T-Rex Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of cohorts (cohort) \| cohort	2
Number of patients, cohort one (patient)	18
Number of patients, cohort two (patient)	93

The Business - Financial Information (Details) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Feb. 29, 2016	Dec. 31, 2016	Mar. 31, 2016	Mar. 10, 2016
Subsequent Event [Line Items]
Share Price	$ 1.00			$ 0.705
Number of consecutive days, share price under $1.00	30 days
Number of consecutive trading days, required above $1.00, to not be delisted	10 days
Period in which to meet consecutive trading day threshold to not be delisted	180 days
Number of days after the initial period to meet consecutive trading day requirement to not be delisted	180 days
PCT Allendale, LLC [Member]
Subsequent Event [Line Items]
Purchase Obligation			$ 4.4
Hitachi Chemical Co., LTD [Member]
Subsequent Event [Line Items]
Proceeds From Licensing Agreements		$ 25.0
Hitachi Chemical Co., LTD [Member] \| PCT Allendale, LLC [Member]
Subsequent Event [Line Items]
Proceeds From Licensing Agreements		10.0
Hitachi Chemical Co., LTD [Member] \| Caladrius Biosciences, Inc. [Member]
Subsequent Event [Line Items]
Proceeds From Licensing Agreements		$ 15.0

The Business - Principles of Consolidation(Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Subsidiary or Equity Method Investee [Line Items]
Change in Ownership in Subsidiary	$ 0	$ 0	$ 0
NeoStem, Inc. [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Athelos Corporation [Member] \| Becton Dickson [Member]
Subsidiary or Equity Method Investee [Line Items]
Noncontrolling Interest in Variable Interest Entity	$ 0.028
Location [Member] \| NeoStem, Inc. [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| NeoStem Therapies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Stem Cell Technologies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Amorcyte, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Progenitor Cell Therapy, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| NeoStem Family Storage, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Athelos Corporation [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| PCT Allendale, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
UNITED STATES \| NeoStem Therapies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Stem Cell Technologies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Amorcyte, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Progenitor Cell Therapy, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| NeoStem Family Storage, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Athelos Corporation [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	97.00%
UNITED STATES \| PCT Allendale, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| NeoStem Oncology [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Entity Location	United States of America

Summary of Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Details)	Jun. 30, 2015 USD ($) reporting_unit	Dec. 31, 2015 USD ($) reporting_unit	Dec. 31, 2014 USD ($) reporting_unit	Dec. 31, 2013 USD ($)
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage		0.00%
Number of reporting units (reporting_unit) \| reporting_unit	2	2	2
Goodwill, impairment		$ 18,200,000	$ 0
Clinical Services Reimbursement		$ 3,400,000	$ 3,700,000	$ 2,100,000
Revene Recognition Period for Cryoperservation Process		24 hours
Building and Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P25Y
Building and Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P30Y
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P8Y
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P12Y
Lab Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P5Y
Lab Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P7Y
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P5Y
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P12Y
Computer Software, Intangible Asset [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P3Y
Computer Software, Intangible Asset [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P5Y
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		life of lease
NeoStem, Inc. [Member]
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage		0.00%
In Process R&D [Member] \| Amorcyte, LLC [Member]
Property, Plant and Equipment [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 9,400,000
In Process R&D [Member] \| CSC Acquisition [Member]
Property, Plant and Equipment [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 34,300,000

Acquisitions Fair value of assets acquired and liabilities (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	May 08, 2014
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents												$ 51,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment												1,041,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other												201,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent												$ 13,901,000
Common stock, shares, issued (shares)												5,329,593
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High												$ 90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net												19,400,000
Business Acquisition, Transaction Costs												33,500,000
Goodwill	$ 7,013,315				$ 25,209,336				$ 7,013,315	$ 25,209,336		14,092,000
Equity Issued in Business Combination, Fair Value Disclosure												21,600,000
Business Combination, Contingent Consideration, Liability	$ 0				$ 18,260,000				$ 0	$ 18,260,000		11,900,000
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.59)	$ (0.21)	$ (0.38)	$ (0.51)	$ (0.32)	$ (0.48)	$ (0.40)	$ (0.49)	$ (1.67)	$ (1.68)	$ (1.90)
Business Combination, Acquired Receivables, Fair Value												45,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets												19,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill												34,290,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable												333,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities												2,014,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net												$ 33,491,000

Acquisitions CSC acquisitions (Details) - USD ($)	3 Months Ended								12 Months Ended
Acquisitions CSC acquisitions (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	May 08, 2014
Business Acquisition [Line Items]
Revenues	$ 7,560	$ 5,888	$ 5,867	$ 3,172	$ 5,276	$ 4,118	$ 4,489	$ 4,056	$ 22,487,566	$ 17,938,790	$ 14,668,455
Common stock, shares, issued (shares)												5,329,593
Business Acquisition, Transaction Costs												$ 33,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents												51,000
Business Combination, Acquired Receivables, Fair Value												45,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets												19,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment												1,041,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other												201,000
Goodwill	7,013,315				25,209,336				7,013,315	25,209,336		14,092,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill												34,290,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable												333,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities												2,014,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent												13,901,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net												33,491,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High												90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net												19,400,000
Equity Issued in Business Combination, Fair Value Disclosure												21,600,000
Business Combination, Contingent Consideration, Liability	$ 0				$ 18,260,000				$ 0	$ 18,260,000		$ 11,900,000
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.59)	$ (0.21)	$ (0.38)	$ (0.51)	$ (0.32)	$ (0.48)	$ (0.40)	$ (0.49)	$ (1.67)	$ (1.68)	$ (1.90)
Net loss									$ (81,010,501)	$ (55,466,246)	$ (39,485,334)
Net Income (Loss) Attributable to Parent	$ (33,197)	$ (11,376)	$ (17,126)	$ (19,187)	$ (11,612)	$ (16,974)	$ (12,605)	$ (13,682)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues										$ 17,939,000	$ 14,668,000
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders										$ (1.68)	$ (1.90)
Net loss										$ (55,467,000)	$ (39,485,000)
Net Income (Loss) Attributable to Parent										(54,873,000)	(38,981,000)
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue										18,649,000	15,471,000
Business Acquisition, Pro Forma Net Income (Loss)										(57,964,000)	(44,790,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual										$ (57,371,000)	$ (44,286,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted										$ (1.51)	$ (1.71)

Availabe-for-Sale-Securities Available-for-Sale-Securities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2014
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 6,874,800	$ 22,358,200
Gross Unrealized Gains	800	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Fair Value, Estimate Not Practicable, Investments	6,875,600	22,359,500
Cash and cash equivalents	6,875,600	15,279,400
Available-for-sale Securities, Current	0	7,080,100
Cash, Cash Equivalents, and Short-term Investments	6,875,600	22,359,500
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Amortized Cost Basis	6,874,800		$ 6,874,800
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value	6,875,600
Available-for-sale Securities, Debt Securities	6,875,600
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	4,740,900	9,317,300
Gross Unrealized Gains	800	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Fair Value, Estimate Not Practicable, Investments	4,741,700	9,318,600
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	837,700	12,791,900
Gross Unrealized Gains	0	0
Money Market Funds, at Carrying Value	837,700	12,791,900
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	249,000	249,000
Gross Unrealized Gains	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Fair Value, Estimate Not Practicable, Investments	249,000	249,000
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	1,047,200	0
Gross Unrealized Gains	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Fair Value, Estimate Not Practicable, Investments	$ 1,047,200	$ 0

Deferred Costs (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Inventory [Line Items]
Deferred costs	$ 2,911,743	$ 2,566,989
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 4,900,000	$ 3,900,000

Property, Plant & Equipment (Details) - USD ($)	12 Months Ended
Property, Plant & Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Buildings and Improvements, Gross	$ 11,478,600	$ 11,298,700
Depreciation, Depletion and Amortization	2,100,000	1,600,000	$ 1,000,000
Property, plant and equipment, net	17,064,900	15,960,731
Machinery and Equipment, Gross	68,300	68,300
Property, Plant and Equipment, Other, Gross	7,461,200	6,324,700
Furniture and Fixtures, Gross	2,320,900	1,166,300
Capitalized Computer Software, Gross	445,700	312,400
Leasehold Improvements, Gross	2,831,500	2,219,600
Property, Plant and Equipment, Gross	24,606,200	21,390,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(7,541,400)	(5,429,300)
Property, Plant and Equipment, Other Types [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 17,064,800	$ 15,960,700

Loss Per Share (Details) - shares	12 Months Ended
Loss Per Share (Details) - shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	6,663,270	4,427,276	2,932,191
Warrant [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,214,033	3,550,956	4,898,266
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	202,776	280,481	78,500

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	May 08, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 90,000,000
Business Combination, Contingent Consideration, Liability	$ 0	$ 18,260,000	$ 11,900,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015	May 08, 2014	Oct. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	$ 0	$ 12,800,000
Percentage of Net Sales						10.00%
Percentage of license cost						30.00%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Available-for-sale Securities	0	7,080,000
Business Combination, Contingent Consideration, Liability	0	18,260,000			$ 11,900,000
Fair Value, Net Asset (Liability)	0	18,260,000
Changes in acquisition-related contingent consideration	(18,260,000)	(3,080,000)	$ 1,900,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Available-for-sale Securities	0	0
Business Combination, Contingent Consideration, Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Available-for-sale Securities	0	7,080,000
Business Combination, Contingent Consideration, Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Available-for-sale Securities	0	0
Business Combination, Contingent Consideration, Liability	$ 0	18,260,000
Amorcyte, LLC [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Business Combination, Contingent Consideration, Liability		$ 5,500,000		$ 0

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Balance as of December 31, 2014		$ 25,209,336
Goodwill impairment		(18,196,000)
Balance as of December 31, 2015		7,013,315	$ 25,209,336
Goodwill, impairment		18,200,000	0
Future Amortization Expense, Year One		570,000
Future Amortization Expense, Year Two		570,000
Future Amortization Expense, Year Three		570,000
Future Amortization Expense, Year Four		570,000
Future Amortization Expense, Year Five		570,000
Future Amortization Expense, after Year Five		27,900
Finite-Lived Intangible Assets, Net		2,877,900	47,560,400
Customer Lists [Member]
Goodwill [Roll Forward]
Balance as of December 31, 2014		25,209,300
Balance as of December 31, 2015		7,013,300	25,209,300
Finite-Lived Intangible Assets, Net		504,900	$ 604,900
Amorcyte, LLC [Member] \| In Process R&D [Member]
Goodwill [Roll Forward]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 9,400,000
CSC Acquisition [Member] \| In Process R&D [Member]
Goodwill [Roll Forward]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 34,300,000

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 5,700,000	$ 50,059,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,822,100)	(2,498,600)
Finite-Lived Intangible Assets, Net	2,877,900	47,560,400
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(495,100)	(395,100)
Finite-Lived Intangible Assets, Net	$ 504,900	604,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,930,900)	(1,540,900)
Finite-Lived Intangible Assets, Net	$ 1,969,100	2,359,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(396,100)	(316,100)
Finite-Lived Intangible Assets, Net	$ 403,900	483,900
Finite-Lived Intangible Assets, Useful Life	10 years
In Process R&D [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 0	43,690,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Net	$ 0	43,690,000
Finite Lived Intangible Assets, Useful Life [String]	Indefinite
VSEL Patent Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 0	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	(246,500)
Finite-Lived Intangible Assets, Net	$ 0	$ 422,500
Finite-Lived Intangible Assets, Useful Life	19 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 605,200	$ 605,200	$ 605,200
Cost of Sales [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	309,100	316,800	390,000
General and Administrative Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	180,000	180,000	180,000
Research and Development Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 116,100	$ 108,400	$ 35,200

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Employee-related Liabilities	$ 2,771.2	$ 2,807.2
Accrued Professional Fees	480.7	495.4
Other Accrued Liabilities	2,946.5	1,020.3
Accrued Liabilities	$ 6,198.4	$ 4,322.9

Debt (Details) - USD ($)	12 Months Ended
Debt (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Sep. 26, 2014
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment	$ 18,200,000
Interest Expense, Long-term Debt	1,300,000	$ 300,000
Notes Payable	1,800,000	$ 1,600,000
Mortgage Loans on Real Estate, Carrying Amount of Mortgages	3,100,000
Proceeds from Issuance of Debt	11,300,000
Debt issuance costs	$ 100,000
Payment Guarantee [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest	8.00%
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	8.50%
NeoStem, Inc. [Member] \| Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	21 months
Long-term Debt [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross			$ 15,000,000
Less than one year [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment	$ 5,300,000
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment	6,700,000
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment	$ 6,200,000

Preferred Stock Convertible Redeemable Series E Preferred Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Net proceeds from issuance of capital stock	$ 36,471,269	$ 16,710,645	$ 58,736,165

Shareholders' Equity (Details) - USD ($)	1 Months Ended	12 Months Ended
Shareholders' Equity (Details) - USD ($)	Nov. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Class of Stock [Line Items]
Proceeds from issuance of common stock		$ 36,471,269	$ 16,710,645	$ 58,736,166
weighted average estimated fair value of restricted stock		$ 2.68	$ 5.44
Stock Issued During Period, Shares, Restricted Stock Award, Gross		928,000	917,907
Proceeds from Warrant Exercises		$ 0	$ 1,720,725	3,028,241
Stock Issued During Period, Value, Warrant Inducements				62,014
Stock Issued During Period, Value, Restricted Stock Award, Gross		2,488,600	4,996,300
Common Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock		$ 19,021	$ 2,959	$ 9,713
Stock Issued During Period, Shares, New Issues		19,021,155	2,959,214	9,712,724
Stock Issued During Period, Value, Warrant Inducements				$ 0
Warrant inducements				0
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock		$ 300,000
Term Of Agreement In Months	24 months
Stock Issued During Period, Shares, Other	842,696	200,000
Discount Applied To Weighted Average Price	5.00%
Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)		500,000,000	500,000,000
Non US Equity Plan [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)					570,000
2009 Equity Plan [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)		8,995,000	5,995,000		450,000	2,375,000	1,775,000	1,375,000	975,000	380,000
US Equity Plan [Member] \| 2015 Equity Plan [Member] [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member] [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)		4,400,000
Initial Reserve Or Shares, Percent Increase Each Year		4.00%
Initial Reserve, Increase In Number Of Shares Each Year		176,000
US Equity Plan [Member] \| 2009 Equity Plan [Member] \| Stock Options [Member] \| 2009 Equity Plan [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)		8,995,000

Shareholders' Equity Components of share-based compensation expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(3,214,033)
Share-based Compensation Expense	$ 9,750,100	$ 11,209,500	$ 6,838,700
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	545,300	494,200	314,000
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	1,811,500	2,058,200	822,200
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 7,393,300	$ 8,657,100	$ 5,702,500
Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)	8,995,000	5,995,000		450,000	2,375,000	1,775,000	1,375,000	975,000	380,000
Stock Options [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)				570,000
2015 Equity Plan [Member] [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member] [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	0
Shares Expired	0
Common stock, shares authorized (shares)	4,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(441,100)
Common Stock, Shares, Outstanding	(3,958,900)
2009 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(80,856)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(1,601,033)
Shares Expired	0
Common stock, shares authorized (shares)	8,995,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(6,113,425)
Common Stock, Shares, Outstanding	(1,199,686)
2003 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2003 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(9,250)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(88,993)
Shares Expired	(43,012)
Common stock, shares authorized (shares)	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(108,745)
Common Stock, Shares, Outstanding	0

Shareholders' Equity Activity for stock options and warrants (Details)	12 Months Ended
	Dec. 31, 2015 USD ($) $ / shares $ / warrant shares	Dec. 31, 2014 USD ($) $ / shares $ / warrant shares	Dec. 31, 2013 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 0	$ 28,600
Common Stock Warrants, Shares		3,550,956
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	13.72	14.12
Weighted Average Remaining Contractual Term warrant outstanding	1 year 3 months 4 days
Weighted Average Remaining Contractual Term, Warrants Outstanding		2 years 1 month 13 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 0	$ 1,000
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Warrants Granted	0
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 0
Warrants Exercised	0
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 0
Warrants Expired	0
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 0
Warrants Canceled	(336,923)
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 17.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 100
shares, vested and expected to vest	3,214,033
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	13.72
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,214,033
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	13.72
weighted Average Remaining Contractual Term, warrants vested	1 year 3 months 4 days
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 0
Aggregate Intrinsic Value, Warrants vested \| $	$ 0
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 0.00	$ 0.00	$ 3.71
US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 6.46	$ 9.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 10 months 17 days	6 years 11 months 5 days
Common stock, shares, outstanding (shares)	3,214,033
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	1 year 3 months 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	6,663,480
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 6.58
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	6 years 9 months 15 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	3,414,388
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 3.01
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Stock Options, Outstanding at December 31, 2011	4,427,234
Stock Options Exercised	0
Stock Options Forfeited	(740,372)
Stock Options Expired	(437,770)
Stock Options, Outstanding at September 30, 2012	6,663,480	4,427,234
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 7.83
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	4.92
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,837,711
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 7.46
Options, Vested, weighted Average Remaining Contractual Term	6 years 1 month 13 days

Shareholders' Equity Total compensation cost related to nonvested awards (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	928,000	917,907
weighted average estimated fair value of restricted stock	$ 2.68	$ 5.44
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 2,488,600	$ 4,996,300
Restricted Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	$ 332,000
Excepted weighted-average period in years of compensation cost to be recognized	1 year 11 months 12 days
Warrant [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	$ 0
Excepted weighted-average period in years of compensation cost to be recognized	0 days
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	$ 3,078,600
Excepted weighted-average period in years of compensation cost to be recognized	3 years 2 months 1 day

Shareholders' Equity Equity Issuances (Details) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended			22 Months Ended
	Nov. 30, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	May 01, 2015	Jun. 30, 2014	May 08, 2014	Mar. 31, 2014
Class of Stock [Line Items]
Common stock, shares, issued (shares)									5,329,593
Proceeds from issuance of common stock			$ 36,471,269	$ 16,710,645	$ 58,736,166
March 2014 Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other						5,100,000
Stock Issued During Period, Shares, New Issues			3,000,000
Proceeds from issuance of common stock			$ 9,400,000			$ 20,300,000
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other		12,500,000
Fair Value Inputs, Offered Quotes		$ 2.00
Proceeds from issuance of common stock		$ 28,800,000
Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other		1,875,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other	842,696		200,000
Term Of Agreement In Months	24 months
Discount Applied To Weighted Average Price	5.00%
Proceeds from issuance of common stock			$ 300,000
Purchase Commitment, Remaining Minimum Amount Committed	$ 30,000,000
Purchase Commitment, Maximum Amount Committed, Shares	11,019,276
May 2015 Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common stock, shares, issued (shares)		364,837
Purchase Commitment, Remaining Minimum Amount Committed							$ 30,000,000			$ 30,000,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common stock, shares, issued (shares)								150,000

Shareholders' Equity Warrants (Details)	12 Months Ended
Shareholders' Equity Warrants (Details)	Dec. 31, 2015 $ / shares
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Warrants Exercised	$ 0

Shareholders' Equity Equity Plan (Details) - USD ($)	12 Months Ended
Shareholders' Equity Equity Plan (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)	8,995,000	5,995,000	450,000	2,375,000	1,775,000	1,375,000	975,000	380,000
Stock Options [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)			570,000
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)	500,000
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	15.00%
ESPP annual cap	$ 25,000
percentage of stock closing price	85.00%
percentage of ESPP closing price	85.00%
Shares, Issued	133,939
Shares, Outstanding	300,620
2015 Equity Plan [Member] [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member] [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Expired	0
Common stock, shares authorized (shares)	4,400,000

Shareholders' Equity Options (Details) - USD ($)	12 Months Ended
Shareholders' Equity Options (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Proceeds from exercise of options	$ 0	$ 271,008	$ 150,658

Share-Based Compensation (Details)	12 Months Ended
Share-Based Compensation (Details)	Dec. 31, 2015 USD ($)
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 3,078,600
Excepted weighted-average period in years of compensation cost to be recognized	3 years 2 months 1 day
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 0
Excepted weighted-average period in years of compensation cost to be recognized	0 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 332,000
Excepted weighted-average period in years of compensation cost to be recognized	1 year 11 months 12 days

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 9,750,100	$ 11,209,500	$ 6,838,700
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	545,300	494,200	314,000
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,811,500	2,058,200	822,200
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	7,393,300	8,657,100	5,702,500
Warrant [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	$ 0	$ 9,600	$ 129,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	0.00%	66.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	0.00%	66.00%	79.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.00%	0.79%	0.32%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	0.00%	0.79%	1.73%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 0.00	$ 0.00	$ 3.71
Stock Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 1.95	$ 4.56	$ 4.29
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	$ 6,133,000	$ 5,387,100	$ 3,375,700
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	71.00%	62.00%	61.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	75.00%	77.00%	79.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.19%	0.12%	0.13%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.14%	3.00%	2.67%

Share-Based Compensation Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	71.00%	62.00%	61.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	75.00%	77.00%	79.00%
Fair Value Assumptions, Weighted Average Volatility Rate	74.00%	74.00%	83.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.19%	0.12%	0.13%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.14%	3.00%	2.67%
Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	0.00%	66.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	0.00%	66.00%	79.00%
Fair Value Assumptions, Weighted Average Volatility Rate	0.00%	74.00%	82.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.00%	0.79%	0.32%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	0.00%	0.79%	1.73%
Minimum [Member] \| Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	2 years	0 years	1 year
Minimum [Member] \| Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	0 years	3 years	2 years
Maximum [Member] \| Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	10 years	10 years	10 years
Maximum [Member] \| Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	0 years	3 years	5 years

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Loss from operations before provision for income taxes and noncontrolling interests	$ (98,254,029)	$ (55,570,448)	$ (38,705,230)
Current Federal Tax Expense (Benefit)	0	0	0
Deferred State and Local Income Tax Expense (Benefit)	(2,548,000)	(263,200)	303,200
Federal Income Tax Expense (Benefit), Continuing Operations	(14,695,500)	159,000	476,900
State and Local Income Tax Expense (Benefit), Continuing Operations	(2,548,000)	(263,200)	303,200
Deferred Federal Income Tax Expense (Benefit)	(14,695,500)	159,000	476,900
Current State and Local Tax Expense (Benefit)	0	0	0
Current Income Tax Expense (Benefit)	$ 0	0	0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%
Operating Loss Carryforwards	$ 221,500,000	177,200,000
Deferred income taxes	(17,243,500)	(104,200)	780,100
Income Tax Expense (Benefit)	(17,243,528)	(104,202)	780,104
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	(33,406,400)	(18,894,000)	(13,159,800)
Income Tax Reconciliation, State and Local Income Taxes	(4,926,900)	(3,435,000)	(3,430,900)
Permanent non deductible expenses for U.S. taxes	706,400	1,094,600	1,798,200
Restatement of Prior Year Income, Net of Tax	556,500	25,500	91,400
Income Tax Reconciliation, Other Adjustments	0	0	(3,822,900)
Income Tax Reconciliation, Change in Enacted Tax Rate	1,300	1,075,700	(1,094,800)
Deferred Tax Assets, Valuation Allowance	20,938,600	20,080,000	20,581,700
Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward	86,537,800	69,047,000	25,727,700
Deferred Tax Assets, Deferred Income	0	0	23,100
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	11,100	(7,800)	15,200
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	12,764,300	9,577,200	5,466,700
Deferred Tax Assets, Goodwill and Intangible Assets	899,700	715,100	287,300
Deferred Tax Assets, Other	0	0	(348,700)
Deferred Tax Assets, Charitable Contribution Carryforwards	423,300	409,800	391,800
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	297,400	296,900	239,700
Deferred Tax Assets, Capital Loss Carryforwards	6,973,000	6,925,100	6,644,500
Deferred Tax Assets, Tax Credit Carryforwards, Other	652,100	609,700	0
Deferred Tax Assets, Net	108,558,700	87,573,000	39,144,700
Deferred Tax Liabilities Accumulated depreciation	(66,000)	(18,800)	0
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	(932,700)	(18,176,300)	(3,599,100)
Deferred Tax Liabilities, Gross	998,700	18,195,100	3,599,100
Deferred Tax Assets (Liabilities), Net	107,560,000	69,377,900	3,599,100
Valuation Allowances and Reserves, Balance	(108,492,700)	(87,554,100)	(39,144,700)
Deferred Tax Liabilities	$ (932,700)	$ (18,176,200)	$ (35,545,600)

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Operating Loss Carry Forward [Abstract]
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	$ (33,406,400)	$ (18,894,000)	$ (13,159,800)
Income Tax Reconciliation, State and Local Income Taxes	(4,926,900)	(3,435,000)	(3,430,900)
Permanent non deductible expenses for U.S. taxes	706,400	1,094,600	1,798,200
Restatement of Prior Year Income, Net of Tax	(556,500)	(25,500)	(91,400)
Income Tax Reconciliation, Other Adjustments	0	0	(3,822,900)
Income Tax Reconciliation, Change in Enacted Tax Rate	1,300	1,075,700	(1,094,800)
Deferred Tax Assets, Tax Credit Carryforwards, Other	652,100	609,700	0
Income Tax Expense (Benefit)	$ (17,243,528)	$ (104,202)	$ 780,104
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies [Abstract]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 2,062,000
Operating Leases, Future Minimum Payments Due [Abstract]
2013	1,863,800
2014	1,034,700
2015	989,400
Thereafter	960,200
Total minimum lease payments	6,910,100
Operating Leases, Rent Expense	$ 1,700,000	$ 1,300,000	$ 1,100,000

Quarterly Financial Data (Details) - USD ($)	3 Months Ended								12 Months Ended
Quarterly Financial Data (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 7,560	$ 5,888	$ 5,867	$ 3,172	$ 5,276	$ 4,118	$ 4,489	$ 4,056	$ 22,487,566	$ 17,938,790	$ 14,668,455
Operating Costs and Expenses	67,269	16,271	31,536	21,260	20,830	20,376	16,919	17,555
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	(33,228)	(11,393)	(17,158)	(19,231)	(11,691)	(17,177)	(12,769)	(13,830)
Net Income (Loss) Attributable to Parent	$ (33,197)	$ (11,376)	$ (17,126)	$ (19,187)	$ (11,612)	$ (16,974)	$ (12,605)	$ (13,682)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.59)	$ (0.21)	$ (0.38)	$ (0.51)	$ (0.32)	$ (0.48)	$ (0.40)	$ (0.49)	$ (1.67)	$ (1.68)	$ (1.90)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 10, 2016	Feb. 29, 2016	Dec. 31, 2014	May 08, 2014
Subsequent Event [Line Items]
Common stock, shares, issued (shares)					5,329,593
Common Stock Warrants, Shares				3,550,956
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares, issued (shares)		1,400,000
Subsidiary, Ownership Interest by Parent	80.10%
Equity Method Investment, Ownership Percentage	19.90%
Contract Receivable	$ 5.6
Common Stock Warrants, Shares		1,400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.00
Share Price		$ 0.705	$ 1.00
Proceeds from Issuance of Warrants	1.0
PCT Allendale, LLC [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase Obligation	4.4
Oxford Finance LLC [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Repayments of debt	$ 7.0
Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent	20.00%
Debt Instrument, Maximum Payment To Lender Based On Receipt Of Proceeds From Eligible Events	$ 3.0
Hitachi Chemical Co., LTD [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Recorded Unconditional Purchase Obligation	$ 19.4
Unrecorded Unconditional Purchase Obligation, Maximum Quantity	15.0